Zum Inhalt springen

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

CUPERTINO, Calif., March 26, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting a poster at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting, to be held in Colorado Springs, CO, USA on March 27-29, 2023. Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC

NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. („INBS“ or the „Company“) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that President and CEO, Harry Simeonidis, and CFO, Spiro Sakiris, are scheduled to present at the LD Micro Invitational XIV Investor Conference to be held on April 8-9, 2024 in New York City. Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

JUPITER, Fla., March 26, 2024 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms today announced the online publication of the manuscript „Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models“ in Nature Communications (“Springer-Nature“), an international journal publishing peer-reviewed research in all fields of science and technology. Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program

JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American Society for Bone and Mineral Research (ASBMR) announced on March 25 2024 that the U.S. Food and Drug Administration (FDA) has communicated to the SABRE (Study to Advance BMD as a Regulatory Endpoint) project team that a ruling to qualify the treatment-related change in bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs would be provided within 10 months. Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

Protein sensor plays a role in lung fibrosis

Researchers at Weill Cornell Medicine have discovered a protein called SEL1L that plays a critical role in clearing collagen from tissue, and which may be a therapeutic target to help prevent fibrosis, scar tissue that interferes with organ function. The paper, published on Feb. 20 in Nature Communications, provides clues that could lead to drug development for diseases like lung fibrosis which have no therapeutic options currently. The researchers discovered a mechanism that cells use to detect collagen production internally and regulate clearance of excess collagen in tissues.  The protein SEL1L acts as a sensor that responds to collagen production by triggering another protein called MRC2 which is involved in the uptake and disposal of collagen. This study suggests that a defective collagen clearing pathway based on MRC2 is a key part of the imbalance in fibrotic disease. The data… 

more »Protein sensor plays a role in lung fibrosis

Sensor erkennt gefährliche Bakterien

Die neu entwickelte Methode weist nur intakte Bakterien nach. Sie nutzt dazu aus, dass Mikroorganismen stets nur bestimmte Körperzellen befallen, die sie an einer Struktur aus speziellen Zuckermolekülen erkennen. Diese sogenannte Glykokalyx ist von Zelltyp zu Zelltyp verschieden. Sie dient den Körperzellen gewissermaßen als Ausweis. Möchte man ein bestimmtes Bakterium fangen, muss man daher nur die entsprechende Erkennungsstruktur in der Glykokalyx seiner bevorzugten Wirtszelle kennen und kann diese dann gewissermaßen als Köder benutzen. Genau das haben die Forschenden auch gemacht. „Wir wollten in unserer Studie einen bestimmten Stamm des Darmbakteriums Escherichia coli – kurz: E. coli – nachweisen“, erklärt Prof. Andreas Terfort vom Institut für Anorganische und Analytische Chemie der Goethe-Universität. „Wir wussten, welche Zellen der Erreger normalerweise infiziert. Das haben wir genutzt, um unseren Chip mit einer künstlichen Glykokalyx zu überziehen, die die Oberfläche dieser Wirtszellen imitiert. An dem… 

more »Sensor erkennt gefährliche Bakterien

Using machine learning to save lives in the ER

Researchers from Osaka University use machine learning to identify patients more likely to survive traumatic injury if treated with tranexamic acid. Early treatment with a drug called tranexamic acid stops excessive bleeding by reducing the body’s ability to break down blood clots. However, tranexamic acid can cause unnecessary drug side effects in patients who do not need it, so it is necessary to select truly effective target patients based on objective criteria. Now, in a study published in Critical Care, researchers from Osaka University have addressed this treatment challenge by identifying subgroups of trauma patients who are more likely to survive if treated with tranexamic acid. The team found these subgroups by examining trauma patients who shared similar traits (also known as phenotypes) https://ccforum.biomedcentral.com/articles/10.1186/s13054-024-04871-w

Ampel diskutiert kontrovers über Enquete-Kommission zu Coronapolitik

Nachdem das Robert-Koch-Institut (RKI) Protokolle seines Coronakrisenstabes veröffentlicht hat, nimmt die Debatte über eine mögliche Enquete-Kommission im Bundestag an Schärfe zu. FDP-Fraktionsvize Wolfgang Kubicki macht dem maßgeblichen Bundesinstitut für Infektionskrankheiten schwere Vorwürfe: „Mich hat nicht überrascht, dass das Robert-Koch-Institut wahrscheinlich als wissenschaftliche Fassade politischer Entscheidungen gedient hat“, sagte er dem „Tagesspiegel“. „Die jetzt freigeklagten Protokolle […] Ampel diskutiert kontrovers über Enquete-Kommission zu Coronapolitik

Rhein verlangt „Fast Lane“ für Fachkräfte aus dem Ausland

Der Finanzplatz Frankfurt hätte womöglich weitaus mehr vom Austritt Großbritanniens aus der Europäischen Union profitiert, wenn in Deutschland ausländische Fachkräfte unkompliziert und schnell anerkannt würden. „Die langen Anerkennungsverfahren sind zunehmend ein Standortrisiko“, sagte der hessische Ministerpräsident Boris Rhein (CDU), dem „Handelsblatt“. „Womöglich wären sonst nach dem Brexit mehr Fachkräfte aus London nach Frankfurt gekommen.“ Der CDU-Politiker […] Rhein verlangt „Fast Lane“ für Fachkräfte aus dem Ausland